Hylvastam

Sodium Hydrogen Carbonate, the active ingredient in Hylvastam, is an excipient presented as an intravenous solution for use as a buffering agent in parenteral preparations. It helps maintain pH balance in intravenous fluids and related pharmaceutical formulations.

GNH USA supplies Hylvastam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide, adhering to EU quality standards and providing reliable global distribution. The product is manufactured under GMP conditions and is available for bulk and unit‑dose requirements.

Hylvastam is used as an excipient to manage pH and stability in various intravenous and parenteral applications.

- Buffering in intravenous admixtures: helps maintain pH stability of IV solutions. - pH adjustment in parenteral nutrition: provides appropriate alkalinity for nutrient compatibility. - Stabilizer in vaccine formulations: supports antigen integrity during storage and administration.

Adverse reactions may occur when sodium hydrogen carbonate is administered intravenously.

Common Side Effects: - Metabolic alkalosis: elevation of blood pH. - Hypernatremia: increased serum sodium levels. - Fluid overload: excess extracellular fluid volume. - Hypokalemia: reduced serum potassium. - Local irritation at infusion site. - Transient hypertension.

Serious or Rare Side Effects: - Severe alkalosis leading to seizures. - Cardiac arrhythmias, especially in patients with underlying heart disease. - Pulmonary edema due to fluid shifts. - Hypocalcemia causing tetany. - Acute renal failure in susceptible individuals. - Anaphylactic reaction to excipient components.

When using Hylvastam, consider the following safety measures.

- Dose adjustment: monitor serum electrolytes and acid‑base status. - Renal function: assess kidney function before administration. - Cardiac status: observe for arrhythmias in patients with heart disease. - Acid‑base balance: avoid use in patients with existing metabolic alkalosis. - Allergy: discontinue if hypersensitivity or anaphylaxis occurs. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Potential drug interactions should be reviewed prior to administration.

Major Interactions (Avoid): - Concurrent calcium‑containing solutions: risk of precipitation. - Co‑administration with other alkalinizing agents: may cause excessive alkalosis. - Use with loop diuretics: can increase sodium load and affect electrolyte balance.

Moderate Interactions (Monitor Closely): - Antihypertensive medications: monitor blood pressure for additive effects. - Nephrotoxic drugs: observe renal function closely. - Insulin therapy: watch for shifts in potassium levels. - Anticoagulants: assess for changes in plasma pH that may affect drug activity.